Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1839100 dose-finding study for cough in idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
jRCT2071240044Phase 2Completed
- Sponsor
- Nippon Boehringer Ingelheim
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of BI 1839100 in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF) and chronic cough (6 arms), sponsored by Nippon Boehringer Ingelheim. Primary endpoint: Change from baseline in 24-hour cough frequency. Started Aug 2024; status: completed.
02
Drugs
BI 1839100
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)chronic cough
Beyond the preview
Go deeper on jRCT2071240044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240044.